Hybrid Event

The Frederick National Laboratory for Cancer Research together with the Frederick County Chamber of Commerce organizes the quarterly Biotech Connector Speaker Series. This event promotes and supports the Frederick County and surrounding areas’ biotech and bioscience community and provides an inside look at local advances.

Please join fellow biotech and bioscience professionals for our fourth quarter series.

Agenda

Antibody Characterization at the Frederick National Lab

Antibodies are among the most commonly used tools in the biological sciences - put to work in many experiments to identify and isolate other molecules. As a result, rigorous antibody validation is performed at the NCI Antibody Characterization Laboratory (ACL), an unbiased intramural reference laboratory located at the Frederick National Laboratory for Cancer Research, to validate antibody specificity and reproducibility. We will discuss available resources and collaboration opportunities.

  • Simona Colantonio, Ph.D., Director, Antibody Characterization Laboratory, Frederick National Laboratory for Cancer Research

Bio

Image
Portrait photo

Dr. Colantonio is an expert in mass spectrometry (MS) applied to biologically relevant molecules. In the early stages of her career, she worked at the Regina Elena National Cancer Institute of Rome, Italy and her studies focused on pharmacokinetics of anti-cancer drugs. Later, she moved to Maryland where she became involved in serum biomarker discovery while working as a guest researcher/post-doctoral fellow at SAIC-Frederick Inc. (now Leidos Biomedical Research). She has been collaborating with the ACL since 2009, when the lab was created. Since then, she has been able to achieve a deep knowledge of antibody/antigen interaction and she has become familiar with the growing number of antibody characterization tools available at the ACL. In 2018 she accepted a position as Visiting Professor at her Alma Mater, La Sapienza University of Rome, Italy (Pharmaceutical Chemistry and Technology Department, March 27th, 2018- April 26th, 2018). She has been serving as ACL Director since September 2019. Dr. Colantonio has obtained the correspondent of a master’s degree in Pharmaceutical Chemistry and Technology and a Pharm. D. from la Sapienza University of Rome, Italy. From the same institution, she has received her Ph.D. in Pharmaceutical Sciences.

Single-Cell Spatial Analysis of Tumor Immune Architecture in DLBCL using Imaging Mass Spectrometry

We used imaging mass cytometry (IMC) on 33 cases of diffuse large B-cell lymphoma (DLBCL) to characterize tumor and immune cell architecture and correlate it to clinicopathological features such as cell of origin, gene mutations, and responsiveness to chemotherapy. To understand the poor response of DLBCL to immune checkpoint inhibitors (ICI), we compared our results to IMC data from Hodgkin lymphoma, a cancer highly responsive to ICI, and observed differences in the expression of PD-L1, PD-1, and TIM-3. We created a spatial classification of tumor cells and identified tumor-centric subregions of immune activation, immune suppression, and immune exclusion within the topology of DLBCL. Finally, the spatial analysis allowed us to identify markers such as CXCR3, which are associated with penetration of immune cells into immune desert regions, with important implications for engineered cellular therapies.

This is the first study to integrate tumor mutational profiling, cell of origin classification, and multiplexed immuno-phenotyping of the TME into a spatial analysis of DLBCL at the single-cell level. We demonstrate that DLBCL has a complex tumor architecture, and that changes in tumor topology can be correlated with clinically relevant features. This analysis identifies candidate biomarkers and therapeutic targets such as TIM-3, CCR4, and CXCR3 that are relevant for combination treatment strategies in immuno-oncology and cellular therapies.

  • Monirath Hav, M.D., Ph.D., Director, Pathology, MacroGenics

Bio

Image
Portrait photo

Dr. Hav is a Translational Research Pathologist focusing on studies of cancer immune microenvironment using multiplex tissue-based imaging platforms as well as biomarker discovery for drug development. She has received the M.D. degree from the University of Health Sciences and has completed her residency in Ghent University, where she later received the Ph.D. degree in Pathology.

Evaluating Antitumor Immunologic Responses with Mass Cytometry Workflows

Despite the incredible progress in the past decade, immunotherapy still only benefits a minority of patients. Understanding the immune responses to cancers remains a critical priority. Given the complexity of the immune microenvironment and the interplay of many cell types, high-parameter profiling has become an essential aspect of cancer immunology research. Mass cytometry, which relies on antibodies conjugated to isotopically enriched heavy metals, offers a versatile and relatively cost-effective platform for evaluating 40+ markers at a per-cell basis in both suspension and tissue biospecimens. This talk will demonstrate how application of mass cytometry workflows enhances the discovery of potential mechanisms of immunotherapy response and resistance.

  • Won Jin Ho, M.D., Assistant Professor of Oncology, Director of Mass Cytometry Facility, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University

Bio

Image
Portrait photo

Dr. Won Jin Ho is an Assistant Professor of Oncology and the Director of Mass Cytometry Facility at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins who focuses on cancer immunology and tumor microenvironment research of gastrointestinal cancers. Dr. Ho leads NIH-funded translational efforts to employ emerging high-parameter tools to empower biomarker discovery and development of novel immunotherapeutic strategies against cancer. Dr. Ho has received awards from ASCO, AACR, DOD, and Harrington Discovery Institute for his work in cancer immunology.

2024-02-22 08:00 2024-02-22 09:00 America/New_York Dynamic World of Antibodies: Characterization and Versatile Applications The Frederick National Laboratory for Cancer Research together with the Frederick County Chamber of Commerce organizes the quarterly Biotech Connector Speaker Series. This event promotes and supports the Frederick County and surrounding areas’ biotech and bioscience community and provides an inside look at local advances. Please join fellow biotech and bioscience professionals for our fourth quarter series. Agenda Antibody Characterization at the Frederick National Lab Antibodies are among the most commonly used tools in the biological sciences - put to work in many experiments to identify and ...

Register
Advanced Technology Research Facility , Advanced Technology Research Facility (ATRF) 8560 Progress Drive, Frederick, MD 21701 Frederick National Laboratory